NSCLC Formulary

Question 1

Bevacizumab

Answer 1

A monoclonal antibody (a lab-made version of a specific immune system protein) that targets vascular endothelial growth factor (VEGF) - Avastin

Question 2

Ramucirumab

Answer 2

A monoclonal antibody (a lab-made version of a specific immune system protein) that targets vascular endothelial growth factor (VEGF) - Cyramza

Question 3

Sotorasib

Answer 3

It works by attaching to the KRAS G12C protein (13% patients, are resistant to EGFR inhibitors) - Lumakras

Question 4

Erlotinib

Answer 4

It used as the first treatment for advanced NSCLCs that have certain mutations in the EGFR gene, can be used with Bevacizumab - Tarceva

Question 5

Afatinib

Answer 5

It used as the first treatment for advanced NSCLCs that have certain mutations in the EGFR gene - Gilotrif

Question 6

Gefitinib

Answer 6

It used as the first treatment for advanced NSCLCs that have certain mutations in the EGFR gene - Iressa

Question 7

Osimertinib

Answer 7

EGFR inhibitor that often works against cells with the T790M mutation. - Tagrisso

Question 8

Dacomitinib

Answer 8

It used as the first treatment for advanced NSCLCs that have certain mutations in the EGFR gene - Vizimpro

Question 9

Amivantamab

Answer 9

Targets two proteins that help cancer cells grow: EGFR and MET, targets EGFR gene with exon 20 insertion mutation - Rybrevant

Question 10

Mobocertinib

Answer 10

Targets EGFR gene with exon 20 insertion mutation -Exkivity

Question 11

Necitumumab

Answer 11

Targets EGFR mutations in squamous cell carcinoma - Portrazza

Question 12

Crizotinib

Answer 12

Targets tumors with ROS1 or ALK mutations - Xalkori

Question 13

Ceritinib

Answer 13

Targets tumors with ALK mutations - (Zykadia)

Question 14

Alectinib

Answer 14

Targets tumors with ALK mutations - (Alecensa)

Question 15

Brigatinib

Answer 15

Targets tumors with ALK mutations - (Alunbrig)

Question 16

Lorlatinib

Answer 16

Targets tumors with ROS1 or ALK mutations - 3rd gen, works against ALK resistant mutations (Lorbrena)

Question 17

Entrectinib

Answer 17

Targets tumors with ROS1 mutations or NTRK mutations - (Rozlytrek)

Question 18

Dabrafenib

Answer 18

Targets tumors with BRAF mutations - (Tafinlar)

Question 19

Trametinib

Answer 19

Targets tumors with MEK mutations and BRAF mutations - (Mekinist)

Question 20

Selpercatinib

Answer 20

Targets tumors with RET mutations (Retevmo)

Question 21

Pralsetinib

Answer 21

Targets tumors with RET mutations (Gavreto)

Question 22

Capmatinib

Answer 22

Targets tumors with MET mutations - (Tabrecta)

Question 23

Tepotinib

Answer 23

Targets tumors with MET mutations - (Tepmetko)

Question 24

Trastuzumab deruxtecan

Answer 24

Targets tumors with HER2 mutations - (Enhertu)

Question 25

Larotrectinib

Answer 25

Targets tumors with NTRK mutations - (Vitrakvi)